Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern
M. Jongeneelen, K. Kaszas, D. Veldman, J. Huizingh, R. van der Vlugt, T. Schouten, D. Zuijdgeest, T. Uil, G. van Roey, N. Guimera, M. Navis, R. Bos, M. Le Gars, J. Sadoff, L. Muchene, , B. Brandenburg
This study evaluates the neutralizing activity of Ad26.COV2.S vaccine sera against SARS-CoV-2 variants, finding reduced effectiveness against Beta and Gamma but less reduction against Delta.
bioRxiv · Jul 1, 2021 · PreprintImmunology